This site is intended for Healthcare Professionals outside the US

MF
PV
  1. Efficacy
  2. Primary Endpoint

JAKAVI demonstrated superior results to best available therapy1

Significantly more patients receiving JAKAVI met the primary composite endpoint compared with those receiving BAT1,2

Primary response at Week 321-3

Significantly more Polycythemia Vera patients receiving JAKAVI, a JAK2 inhibitor, met the primary composite endpoint compared with those receiving BAT

Haematocrit control was defined as the absence of phlebotomy eligibility from Week 8 to Week 32, with no more than one post-randomisation phlebotomy allowed prior to Week 8. Phlebotomy eligibility was defined as haematocrit >45% and ≥3% higher than the baseline or >48%, whichever was lower.1,2 Spleen response was defined as ≥35% reduction from baseline in spleen volume, as assessed by MRI or CT.1,2
  • Among patients who achieved a primary response, 91% had a durable response at Week 481,2
    • Durability of primary response at Week 48 was a key secondary endpoint1,2

77% of patients receiving JAKAVI met at least one component of the primary endpoint1,2

Next: JAKAVI helps patients attain durable haematocrit control

BAT=best available therapy; CT=computed tomography; HCT=haematocrit; MRI=magnetic resonance imaging.

References:

  1. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.
  2. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; May 2019.
  3. Data on file. Novartis Pharma AG. Basel, Switzerland.